Multimorbidity, Polypharmacy, and Neighborhood Disadvantage as Determinants of Cognitive Performance in the ARCHES
Dagem Gebremichael1,2, Semere Bekena3, Ramkrishna K Singh4
1Bursky School of Public Health, Washington University in St. Louis, St. Louis, MO, USA.
Abstract:
BackgroundAfrican American adults experience a disproportionate burden of dementia, shaped by structural and clinical factors that remain unclear.ObjectiveTo quantify associations between multimorbidity, polypharmacy, and cognition in the context of neighborhood disadvantage.MethodsThis study is a cross-sectional analysis of 348 African American adults aged 45-92 years (mean 64.3 years; 73.6% female) from the Aging Research Characterizing Health Exposome via Social drivers (ARCHES) cohort. Comorbidity burden was assessed using a modified Charlson Comorbidity Index (CCI), polypharmacy as ≥5 medications, and neighborhood disadvantage using the Area Deprivation Index (ADI). Linear regression estimated associations with a Preclinical Alzheimer's Cognitive Composite (PACC). The polypharmacy model included modified CCI as a covariate, and effect modification by ADI was assessed using an interaction term between polypharmacy and ADI.ResultsHigher modified CCI was associated with lower cognitive performance (B = -0.071; 95% CI: -0.130, -0.012). Polypharmacy was not independently associated with cognition after modified CCI adjustment (B = -0.081; β = -0.057; p = 0.257). No significant ADI interaction was found (p = 0.064).
Related Concept Videos
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Alzheimer Disease l: Introduction
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Pharmacodynamics in Geriatric Patients: Effects of Age
Alzheimer Disease ll: Pathophysiology
